PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL: Research Article: Pioglitazone for Bipolar Depression
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The antidepressive effect of pioglitazone has been noted in patients with major depressive disorder in absence of metabolic syndrome. This study was conducted to evaluate the safety and efficacy of pioglitazone in patients with bipolar depression without concomitant metabolic syndrome or diabetes. METHOD: Forty-eight outpatients with the diagnosis of bipolar I disorder and a major depressive episode participated in a parallel, randomized, double-blind, placebo-controlled trial, and 44 patients underwent 6-week treatment with either pioglitazone (30 mg/day) or placebo as an adjunctive treatment to lithium. Therapeutic serum lithium levels of 0.6-0.8 mEq/L were required for two or more consecutive weeks immediately before starting pioglitazone and during the 6-week study. Patients were evaluated using Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) at baseline and weeks 1, 2, 4, and 6. The primary outcome was to evaluate the efficacy of pioglitazone in improving the depressive symptoms. RESULT: General linear model repeated measures showed significant effect for time × treatment interaction on the HDRS scores [F(2.78, 116.65) = 4.77, P = .005]. Significantly greater reduction was observed in HDRS scores in the pioglitazone group than the placebo group from baseline HDRS score at weeks 2, 4, and 6, P = .003, .006, and .006, respectively. No serious adverse event was observed. CONCLUSION: This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 11×
“Baseline YMRS scores were not significantly different between the pioglitazone and the placebo groups (5.23 ± 0.97 vs. 5.32 ± 1.04, respectively [MD (95% CI) = –0.09 (–0.70 to 0.52), t (42) = −0.30, P = .77]).”
MethodInfluentialThe Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
Machado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195 · cited 1×
“The delayed antidepressant effect is associated with significant morbidity and increased suicidal risk.[7, 8] Therefore, finding therapeutic strategies with rapid onset and more pronounced effect would have considerable impact on public health.”
BackgroundKashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116 · cited 1×
“showed that despite comparable insulin-sensitization effect of pioglitazone and metformin, pioglitazone was significantly superior to metformin in reduction of depressive symptoms.[30] Supporting results of the previous study, it has been shown that antidepressant-like activity of pioglitazone in the mouse forced swim…”
ResultSelf-citationKemp, D. E., Ismail-Beigi, F., Ganocy, S. J., Conroy, C., Gao, K., Obral, S., Fein, E., Findling, R. L., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.033 · Cited by 109 · cited 3×
“[14] Pioglitazone administration was associated with significant reduction in depressive symptoms along with increase in insulin sensitization and improvement in metabolic biomarkers in both bipolar and unipolar depression in these studies.[13, 14] In a randomized controlled trial, Kashani et al.”
Background
Research works printed but not linked: 26
- Calabrese, 2004, Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample, J Clin Psychiatry, 65, 1499, 10.4088/JCP.v65n1109 · DOI · Paper page
- Simon, 2007, Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression, J Clin Psychiatry, 68, 1237, 10.4088/JCP.v68n0811 · DOI · Paper page
- Nivoli, 2011, New treatment guidelines for acute bipolar depression: a systematic review, J Affect Disord, 129, 14, 10.1016/j.jad.2010.05.018 · DOI · Paper page
- Association, 2002, Practice guideline for the treatment of patients with bipolar disorder (revision), Am J Psychiatry, 159, 1
- Jick, 2004, Antidepressants and the risk of suicidal behaviors, JAMA, 292, 338, 10.1001/jama.292.3.338 · DOI · Paper page
- Yatham, 2009, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009, Bipolar Disord, 11, 225, 10.1111/j.1399-5618.2009.00672.x · DOI · Paper page
- Spiegelman, 1998, PPAR-gamma: adipogenic regulator and thiazolidinedione receptor, Diabetes, 47, 507, 10.2337/diabetes.47.4.507 · DOI · Paper page
- Kaiser, 2009, A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis, J Neuroimmunol, 211, 124, 10.1016/j.jneuroim.2009.04.011 · DOI
- Miller, 2011, Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease, Ann Pharmacother, 45, 1416, 10.1345/aph.1Q238 · DOI · Paper page
- Kemp, 2014, PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression, CNS Drugs, 28, 571, 10.1007/s40263-014-0158-2 · DOI · Paper page
- Kemp, 2010, Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome, Bipolar Disord, 12, 404, 10.1111/j.1399-5618.2010.00823.x · DOI · Paper page
- Kemp, 2009, Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome, Am J Psychiatry, 166, 619, 10.1176/appi.ajp.2008.08081195 · DOI · Paper page
- Koponen, 2008, Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study, J Clin Psychiatry, 69, 178, 10.4088/JCP.v69n0202 · DOI · Paper page
- Mathew, 2008, Novel drugs and therapeutic targets for severe mood disorders, Neuropsychopharmacology, 33, 2080, 10.1038/sj.npp.1301652 · DOI · Paper page
- Salehi-Sadaghiani, 2012, NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice, Psychopharmacology, 223, 345, 10.1007/s00213-012-2722-0 · DOI
- Sepanjnia, 2012, Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial, Neuropsychopharmacology, 37, 2093, 10.1038/npp.2012.58 · DOI · Paper page
- Cuellar, 2005, Distinctions between bipolar and unipolar depression, Clin Psychol Rev, 25, 307, 10.1016/j.cpr.2004.12.002 · DOI · Paper page
- Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Third Report of the National Cholesterol Education Program (NCEP), 2002, Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
- Zeinoddini, 2014, L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial, J Psychiat Res, 59, 125, 10.1016/j.jpsychires.2014.08.016 · DOI
- Amrollahi, 2011, Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania, J Affect Disord, 129, 327, 10.1016/j.jad.2010.08.015 · DOI
- Abolfazli, 2011, Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression, Depress Anxiety, 28, 297, 10.1002/da.20801 · DOI · Paper page
- Abbasi, 2012, Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study, J Affect Disord, 141, 308, 10.1016/j.jad.2012.03.033 · DOI · Paper page
- Shahmansouri, 2014, A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients, J Affect Disord, 155, 216, 10.1016/j.jad.2013.11.003 · DOI
- Sadaghiani, 2011, Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway, Behav Brain Res, 224, 336, 10.1016/j.bbr.2011.06.011 · DOI
- Vlckova, 2010, Hypoglycaemia with pioglitazone: analysis of data from the prescription-event monitoring study, J Eval Clin Pract, 16, 1124, 10.1111/j.1365-2753.2009.01280.x · DOI · Paper page
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Wójtowicz, S., Strosznajder, A. K., Jeżyna, M., & Strosznajder, J. B. (2020) · Neurochemical Research · doi:10.1007/s11064-020-02993-5 · Cited by 327
Rosenblat, J. D., Kakar, R., Berk, M., Kessing, L. V., Vinberg, M., Baune, B. T., Mansur, R. B., Brietzke, E., Goldstein, B. I., & McIntyre, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12373 · Cited by 199
Bipolar Disorder and Inflammation
Rosenblat, J. D., & McIntyre, R. S. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.09.006 · Cited by 186
Rosenblat, J. D., Brietzke, E., Mansur, R. B., Maruschak, N. A., Lee, Y., & McIntyre, R. S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.058 · Cited by 172
Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes
Lyra e Silva, N. D. M., Lam, M. P., Soares, C. N., Munoz, D. P., Milev, R., & De Felice, F. G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00057 · Cited by 164
Revisiting inflammation in bipolar disorder
Fries, G. R., Walss-Bass, C., Bauer, M. E., & Teixeira, A. L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.006 · Cited by 147
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Arabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89
Self-citationAbbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.049 · Cited by 70
Self-citationDomi, E., Uhrig, S., Soverchia, L., Spanagel, R., Hansson, A. C., Barbier, E., Heilig, M., Ciccocioppo, R., & Ubaldi, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4127-15.2016 · Cited by 61
“This finding is particularly important because recent clinical data have provided preliminary evidence for the efficacy of pioglitazone and rosiglitazone in attenuating depression and bipolar disorder in patients (Kemp et al., 2014; Zeinoddini et al., 2015).”
BackgroundResultAnti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53
Alamdarsaravi, M., Ghajar, A., Noorbala, A.-A., Arbabi, M., Emami, A., Shahei, F., Mirzania, M., Jafarinia, M., Afarideh, M., & Akhondzadeh, S. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.05.029 · Cited by 43
“…17-item rating scale that has been widely applied in psychiatric studies to measure the severity of depressive symptoms and also has been used to evaluate treatment efficacy and severity of depressive symptoms in several clinical trials in Iran (Abbasi et al., 2015; Zeinoddini et al., 2014, 2015).”
MethodSelf-citationMohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015592215 · Cited by 39
Self-citation
Metadata
- Authors
- Zeinoddini, A., Sorayani, M., Hassanzadeh, E., Arbabi, M., Farokhnia, M., Salimi, S., Ghaleiha, A., & Akhondzadeh, S.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2015-01-23
- Volume
- 32
- Issue
- 3
- Pages
- 167-173
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W1911808475
- Cited by
- 111
- References
- 6
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 221 d)
- Funders
- Tehran University of Medical Sciences (16043)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.